Journal of HIV Therapy

Issue Number

Latest documents

• SILCAAT and ESPRIT: taking stock.
• Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.
• A review of the use of activation markers in Africa.
• HIV immunology: what lessons can we learn from recent vaccine trials?
• Lymphocyte activation in HIV-1 infection: time for quality control.
• Immune activation and the pathogenesis of HIV disease: implications for therapy.
• Inflammation and gut permeability.
• HIV as an inflammatory disease.
• HIV, atherosclerosis and inflammation: implications for treatment.
• Lymphoid and histiocytic proliferations in HIV-positive patients: problems in diagnosis.

Featured documents

• Targeting the HIV integration process in antiviral therapy.
• A review of the use of activation markers in Africa.
• Lymphocyte activation in HIV-1 infection: time for quality control.
• Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.
• Neuroimaging of CNS involvement in HIV.
• Elevated liver enzymes in HIV monoinfected patients on HIV therapy: what are the implications?
• Key clinical trials of non-nucleoside reverse transcriptase inhibitors in the treatment of chronic HIV-1 infection in adults.
• HIV, atherosclerosis and inflammation: implications for treatment.
• Differentiating HIV-associated non-Hodgkin's lymphomas with similar plasmacellular differentiation.
• The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.